Loading...

Indivior

DB:2IVA
Snowflake Description

Good value with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2IVA
DB
£328M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • Indivior has significant price volatility in the past 3 months.
2IVA Share Price and Events
7 Day Returns
-0.8%
DB:2IVA
1%
DE Pharmaceuticals
-3.6%
DE Market
1 Year Returns
-91.7%
DB:2IVA
-30.1%
DE Pharmaceuticals
-11.8%
DE Market
2IVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Indivior (2IVA) -0.8% -14.3% -63.6% -91.7% -82% -
DE Pharmaceuticals 1% -3.3% -14.3% -30.1% -23.4% 7%
DE Market -3.6% -2.1% -0.8% -11.8% 12% 5.8%
1 Year Return vs Industry and Market
  • 2IVA underperformed the Pharmaceuticals industry which returned -30.1% over the past year.
  • 2IVA underperformed the Market in Germany which returned -11.8% over the past year.
Price Volatility
2IVA
Industry
5yr Volatility vs Market

2IVA Value

 Is Indivior undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Indivior to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Indivior.

DB:2IVA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2IVA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 21%) (71.82%))
1.002
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.002 * 5.96%)
6.2%

Discounted Cash Flow Calculation for DB:2IVA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Indivior is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:2IVA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.2%)
2019 -347.95 Analyst x2 -327.64
2020 -136.60 Analyst x2 -121.12
2021 -24.00 Analyst x1 -20.04
2022 -11.00 Analyst x1 -8.65
2023 108.00 Analyst x1 79.95
2024 188.90 Est @ 74.9% 131.68
2025 288.07 Est @ 52.5% 189.10
2026 394.14 Est @ 36.82% 243.62
2027 495.99 Est @ 25.84% 288.69
2028 586.05 Est @ 18.16% 321.20
Present value of next 10 years cash flows $776.79
DB:2IVA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $586.05 × (1 + 0.23%) ÷ (6.2% – 0.23%)
$9,838.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $9,838.91 ÷ (1 + 6.2%)10
$5,392.38
DB:2IVA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $776.79 + $5,392.38
$6,169.17
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,169.17 / 730.03
$1.58
DB:2IVA Discount to Share Price
Calculation Result
Exchange Rate USD/GBP
(Reporting currency to currency of LSE:INDV)
0.793
Value per Share
(GBP)
= Value per Share in USD x Exchange Rate (USD/GBP)
= $8.45 x 0.793
£6.7
Value per share (EUR) From above. €35.80
Current discount Discount to share price of €2.40
= -1 x (€2.40 - €35.80) / €35.80
93.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Indivior is available for.
Intrinsic value
>50%
Share price is €2.4 vs Future cash flow value of €35.8
Current Discount Checks
For Indivior to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Indivior's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Indivior's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Indivior's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Indivior's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2IVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.34
LSE:INDV Share Price ** LSE (2019-06-14) in GBP £0.45
LSE:INDV Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.261 $0.57
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.7x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Indivior.

DB:2IVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:INDV Share Price ÷ EPS (both in USD)

= 0.57 ÷ 0.34

1.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Indivior is good value based on earnings compared to the DE Pharmaceuticals industry average.
  • Indivior is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Indivior's expected growth come at a high price?
Raw Data
DB:2IVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-5.3%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.99x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

DB:2IVA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 1.66x ÷ -5.3%

-0.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Indivior earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Indivior's assets?
Raw Data
DB:2IVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.18
LSE:INDV Share Price * LSE (2019-06-14) in GBP £0.45
LSE:INDV Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.261 $0.57
Germany Pharmaceuticals Industry PB Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 1.76x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.76x
DB:2IVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:INDV Share Price ÷ Book Value per Share (both in USD)

= 0.57 ÷ 0.18

3.11x

* Primary Listing of Indivior.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Indivior is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Indivior's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Indivior has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2IVA Future Performance

 How is Indivior expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Indivior expected to grow at an attractive rate?
  • Indivior's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Indivior's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Indivior's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2IVA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2IVA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -5.3%
DB:2IVA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -4%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.1%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2IVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2IVA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 641 110 130 1
2022-12-31 556 -9 1
2021-12-31 677 -11 2
2020-12-31 518 16 2
2019-12-31 551 -275 -2 2
DB:2IVA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 988 413 248
2018-12-31 1,005 303 275
2018-09-30 1,033 276 107
2018-06-30 1,063 210 68
2018-03-31 1,083 260 71
2017-12-31 1,093 295 58
2017-09-30 1,087 360 281
2017-06-30 1,080 409 81
2017-03-31 1,065 370 65
2016-12-31 1,058 407 35
2016-09-30 1,047 326 -6
2016-06-30 1,028 283 191

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Indivior's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Indivior's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2IVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Indivior Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2IVA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.17 0.17 0.17 1.00
2022-12-31 0.01 0.01 0.01 1.00
2021-12-31 0.29 0.33 0.26 2.00
2020-12-31 -0.07 -0.06 -0.08 2.00
2019-12-31 -0.02 -0.02 -0.02 2.00
DB:2IVA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.34
2018-12-31 0.38
2018-09-30 0.15
2018-06-30 0.09
2018-03-31 0.10
2017-12-31 0.08
2017-09-30 0.39
2017-06-30 0.11
2017-03-31 0.09
2016-12-31 0.05
2016-09-30 -0.01
2016-06-30 0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Indivior will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Indivior's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Indivior has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2IVA Past Performance

  How has Indivior performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Indivior's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Indivior's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Indivior's 1-year earnings growth exceeds its 5-year average (249.3% vs -27.4%)
  • Indivior's earnings growth has exceeded the DE Pharmaceuticals industry average in the past year (249.3% vs 4.5%).
Earnings and Revenue History
Indivior's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Indivior Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2IVA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 988.00 248.00 489.00 63.00
2018-12-31 1,005.00 275.00 518.00 67.00
2018-09-30 1,033.00 107.00 721.00 72.00
2018-06-30 1,063.00 68.00 759.00 79.00
2018-03-31 1,083.00 71.00 730.00 80.00
2017-12-31 1,093.00 58.00 707.00 89.00
2017-09-30 1,087.00 281.00 482.00 99.00
2017-06-30 1,080.00 81.00 434.00 104.00
2017-03-31 1,065.00 65.00 444.00 113.00
2016-12-31 1,058.00 35.00 456.00 119.00
2016-09-30 1,047.00 -6.00 443.00 128.00
2016-06-30 1,028.00 191.00 440.00 137.00
2016-03-31 1,021.00 201.00 423.00 143.00
2015-12-31 1,014.00 228.00 408.00 132.00
2015-09-30 1,037.00 268.00 388.00 143.00
2015-06-30 1,058.00 314.00 368.00 131.00
2015-03-31 1,085.00 361.00 332.00 119.00
2014-12-31 1,115.00 403.00 343.00 115.00
2014-09-30 1,147.00 443.00 325.00 99.00
2013-12-31 1,216.00 489.00 341.00 76.00
2012-12-31 1,339.00 607.00 320.00 41.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Indivior made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • Indivior used its assets more efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Indivior's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Indivior's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Indivior has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2IVA Health

 How is Indivior's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Indivior's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Indivior is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Indivior's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Indivior's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Indivior Company Filings, last reported 2 months ago.

DB:2IVA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 133.00 297.00 1,054.00
2018-12-31 66.00 241.00 924.00
2018-09-30 48.00 329.00 901.00
2018-06-30 -43.00 477.00 951.00
2018-03-31 -101.00 483.00 895.00
2017-12-31 -203.00 482.00 863.00
2017-09-30 -74.00 470.00 806.00
2017-06-30 -133.00 481.00 792.00
2017-03-31 -211.00 524.00 729.00
2016-12-31 -295.00 535.00 692.00
2016-09-30 -382.00 546.00 586.00
2016-06-30 -167.00 551.00 577.00
2016-03-31 -230.00 594.00 543.00
2015-12-31 -279.00 605.00 467.00
2015-09-30 -289.00 689.00 552.00
2015-06-30 -334.00 702.00 523.00
2015-03-31 -408.00 698.00 466.00
2014-12-31 -475.00 736.00 331.00
2014-09-30 -45.00 0.00 32.00
2013-12-31 -66.00 0.00 7.00
2012-12-31 145.00 0.00 25.00
  • Indivior's level of debt (180.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 180.5% today).
  • Debt is well covered by operating cash flow (172.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 42.1x coverage).
X
Financial health checks
We assess Indivior's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Indivior has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2IVA Dividends

 What is Indivior's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Indivior dividends. Estimated to be 0% next year.
If you bought €2,000 of Indivior shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Indivior's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Indivior's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2IVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2IVA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
DB:2IVA Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2017-11-02 0.000 0.000
2017-07-27 0.000 0.000
2017-05-03 0.000 0.000
2017-03-23 0.000 0.000
2017-02-22 0.000 0.000
2016-07-14 0.127 3.209
2016-04-08 0.127 4.725
2016-02-18 0.127 5.461
2015-11-03 0.064 2.491
2015-07-29 0.064 1.845

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Indivior has not reported any payouts.
  • Unable to verify if Indivior's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Indivior's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Indivior has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Indivior's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Indivior's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Indivior afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Indivior has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2IVA Management

 What is the CEO of Indivior's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shaun Thaxter
COMPENSATION $1,009,700
TENURE AS CEO 5.4 years
CEO Bio

Mr. Shaun Thaxter has been the Chief Executive Officer of Indivior PLC since 2014. Mr. Thaxter served as the President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc. since 2009. Mr. Thaxter joined Reckitt Benckiser Pharmaceuticals in 2005. He has spearheaded the successful growth and development of RBP since launching the US Suboxone business in 2003. Following his formal appointment as President of RBP in 2005, he has led RBP through sustained growth, building a life-cycle management pipeline and expanded addiction franchise which grew from zero to a peak of $1.3 billion net revenue. Mr. Thaxter joined Reckitt & Colman in 1995 as Senior Brand Manager and advanced to Category Manager within the UK Healthcare business. Following the 1999 merger with Benckiser, he served as Global Category Manager for the prescription product portfolio. He has Over 25 years of experience in pharmaceutical and prescription products industry. Mr. Thaxter has been an Executive Director of Indivior PLC since November 04, 2014. He graduated from King's College, London with a Joint Honours BSc in Biochemistry.

CEO Compensation
  • Shaun's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Shaun's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Indivior management team in years:

4.7
Average Tenure
  • The tenure for the Indivior management team is about average.
Management Team

Shaun Thaxter

TITLE
CEO & Executive Director
COMPENSATION
$1M
TENURE
5.4 yrs

Mark Crossley

TITLE
CFO & Executive Director
COMPENSATION
$551K
TENURE
2.3 yrs

Christian Heidbreder

TITLE
Chief Scientific Officer

Jason Thompson

TITLE
Vice President of Investor Relations

Javier Rodriguez

TITLE
Chief Legal Officer

Cindy Cetani

TITLE
Chief Integrity & Compliance Officer
TENURE
0.7 yrs

Debby Betz

TITLE
Chief Corporate Affairs & Communications Officer
TENURE
4.7 yrs

Jon Fogle

TITLE
Chief Human Resources Officer
TENURE
4.7 yrs

Richard Simkin

TITLE
Chief Commercial & Strategy Officer

Frank Stier

TITLE
Chief Manufacturing & Supply Officer
TENURE
4.7 yrs
Board of Directors Tenure

Average tenure and age of the Indivior board of directors in years:

4.6
Average Tenure
58.5
Average Age
  • The tenure for the Indivior board of directors is about average.
Board of Directors

Howard Pien

TITLE
Chairman
AGE
60

Shaun Thaxter

TITLE
CEO & Executive Director
COMPENSATION
$1M
TENURE
4.6 yrs

Mark Crossley

TITLE
CFO & Executive Director
COMPENSATION
$551K
TENURE
2.3 yrs

Lorna Parker

TITLE
Non-Executive Director
TENURE
4.6 yrs

Dan Phelan

TITLE
Non-Executive Director
AGE
68
TENURE
4.6 yrs

Chris Schade

TITLE
Non-Executive Director
AGE
57
TENURE
4.6 yrs

Daniel Tassé

TITLE
Senior Independent Director
AGE
58
TENURE
2.8 yrs

Tom McLellan

TITLE
Non-Executive Director
TENURE
4.6 yrs

Liz Zlatkus

TITLE
Non-Executive Director
AGE
59
TENURE
2.8 yrs

Tatjana May

TITLE
Non-Executive Director
AGE
53
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Indivior insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. May 19 Buy Daniel Phelan Individual 14. May 19 14. May 19 10,000 €2.48 €24,798
X
Management checks
We assess Indivior's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Indivior has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2IVA News

Simply Wall St News

2IVA Company Info

Description

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company’s product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Details
Name: Indivior PLC
2IVA
Exchange: DB
Founded: 2014
£368,507,805
730,030,588
Website: http://www.indivior.com
Address: Indivior PLC
10710 Midlothian Turnpike,
North Chesterfield,
Virginia, 23235,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE INDV Ordinary Shares London Stock Exchange GB GBP 23. Dec 2014
OTCPK IZQV.F Ordinary Shares Pink Sheets LLC US USD 23. Dec 2014
BATS-CHIXE INDVL Ordinary Shares BATS 'Chi-X Europe' GB GBP 23. Dec 2014
OTCPK INVV.Y SPONSORED ADR Pink Sheets LLC US USD 30. Dec 2014
DB 2IVA SPONSORED ADR Deutsche Boerse AG DE EUR 30. Dec 2014
Number of employees
Current staff
Staff numbers
915
Indivior employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 21:48
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.